BACKGROUND: Highly active antiretroviral therapy (HAART) drastically reduces mother-to-child transmission of HIV, but where breastfeeding is the only safe infant feeding option, HAART for the prevention of mother-to-child transmission needs to be evaluated in relation to both HIV transmission and infant mortality. DESIGN AND METHODS: One hundred and two > or = 18-year old women on HAART in rural Uganda who delivered one or more live infants between March 1, 2003 and January 1, 2007 were enrolled in a prospective study to assess HIV transmission and infant survival. All pregnant women were counseled to exclusively breastfeed for 3-6 months according to national guidelines at the time. Infants were followed-up for > or = 7 months and were offered HIV polymerase chain reaction testing quarterly from 6 weeks of age until > or = 6 weeks after complete weaning. RESULTS: Of 118 infants born during follow-up, 109 (92%) were breastfed. Median durations of exclusive and total breastfeeding were 4 months (interquartile range 3-6) and 5 months (interquartile range 3-7), respectively. None of the infants tested HIV polymerase chain reaction positive over follow-up but 16 infants died without a definitive HIV status at a median age of 2.6 months. In total, 23 (19%) infants died during follow-up at a median age of 3.7 months; 15 (65%) of whom with severe diarrhea and/or vomiting in the week preceding their death. In multivariate analysis, there was a 6-fold greater risk of death among infants breastfed for less than 6 months independent of maternal CD4 count closest to delivery, maternal marital status or maternal death (adjusted hazard ratio = 6.19; 95% confidence interval 1.41-27.0, P = 0.015). CONCLUSIONS: In resource-constrained settings, HIV-infected pregnant women should be assessed for HAART eligibility and treated as needed without delay, and should be encouraged to breastfeed their infants for at least 6 months.
BACKGROUND: Highly active antiretroviral therapy (HAART) drastically reduces mother-to-child transmission of HIV, but where breastfeeding is the only safe infant feeding option, HAART for the prevention of mother-to-child transmission needs to be evaluated in relation to both HIV transmission and infant mortality. DESIGN AND METHODS: One hundred and two > or = 18-year old women on HAART in rural Uganda who delivered one or more live infants between March 1, 2003 and January 1, 2007 were enrolled in a prospective study to assess HIV transmission and infant survival. All pregnant women were counseled to exclusively breastfeed for 3-6 months according to national guidelines at the time. Infants were followed-up for > or = 7 months and were offered HIV polymerase chain reaction testing quarterly from 6 weeks of age until > or = 6 weeks after complete weaning. RESULTS: Of 118 infants born during follow-up, 109 (92%) were breastfed. Median durations of exclusive and total breastfeeding were 4 months (interquartile range 3-6) and 5 months (interquartile range 3-7), respectively. None of the infants tested HIV polymerase chain reaction positive over follow-up but 16 infants died without a definitive HIV status at a median age of 2.6 months. In total, 23 (19%) infants died during follow-up at a median age of 3.7 months; 15 (65%) of whom with severe diarrhea and/or vomiting in the week preceding their death. In multivariate analysis, there was a 6-fold greater risk of death among infants breastfed for less than 6 months independent of maternal CD4 count closest to delivery, maternal marital status or maternal death (adjusted hazard ratio = 6.19; 95% confidence interval 1.41-27.0, P = 0.015). CONCLUSIONS: In resource-constrained settings, HIV-infected pregnant women should be assessed for HAART eligibility and treated as needed without delay, and should be encouraged to breastfeed their infants for at least 6 months.
Authors: Denise J Jamieson; Charles S Chasela; Michael G Hudgens; Caroline C King; Athena P Kourtis; Dumbani Kayira; Mina C Hosseinipour; Deborah D Kamwendo; Sascha R Ellington; Jeffrey B Wiener; Susan A Fiscus; Gerald Tegha; Innocent A Mofolo; Dorothy S Sichali; Linda S Adair; Rodney J Knight; Francis Martinson; Zebrone Kacheche; Alice Soko; Irving Hoffman; Charles van der Horst Journal: Lancet Date: 2012-04-26 Impact factor: 79.321
Authors: Valerie L Flax; Margaret E Bentley; Charles S Chasela; Dumbani Kayira; Michael G Hudgens; Rodney J Knight; Alice Soko; Denise J Jamieson; Charles M van der Horst; Linda S Adair Journal: J Nutr Date: 2012-05-30 Impact factor: 4.798
Authors: Alison C Roxby; Jennifer A Unger; Jennifer A Slyker; John Kinuthia; Andrew Lewis; Grace John-Stewart; Judd L Walson Journal: Curr HIV/AIDS Rep Date: 2014-06 Impact factor: 5.071
Authors: Taha E Taha; Donald R Hoover; Shu Chen; Newton I Kumwenda; Linda Mipando; Kondwani Nkanaunena; Michael C Thigpen; Allan Taylor; Mary Glenn Fowler; Lynne M Mofenson Journal: Clin Infect Dis Date: 2011-08 Impact factor: 9.079
Authors: Roger L Shapiro; Douglas Kitch; Anthony Ogwu; Michael D Hughes; Shahin Lockman; Kathleen Powis; Sajini Souda; Claire Moffat; Sikhulile Moyo; Kenneth McIntosh; Erik van Widenfelt; Sheryl Zwerski; Loeto Mazhani; Joseph Makhema; Max Essex Journal: AIDS Date: 2013-07-31 Impact factor: 4.177
Authors: Pamela M Murnane; Stephen M Arpadi; Moses Sinkala; Chipepo Kankasa; Mwiya Mwiya; Prisca Kasonde; Donald M Thea; Grace M Aldrovandi; Louise Kuhn Journal: Int J Epidemiol Date: 2010-05-19 Impact factor: 7.196
Authors: Carina Marquez; Jaffer Okiring; Gabriel Chamie; Theodore D Ruel; Jane Achan; Abel Kakuru; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Grant Dorsey Journal: J Trop Pediatr Date: 2014-08-21 Impact factor: 1.165
Authors: Tin Tin Sint; Ronnie Lovich; Wendy Hammond; Maria Kim; Sara Melillo; Lydia Lu; Pamela Ching; Jennifer Marcy; Nigel Rollins; Emilia H Koumans; Amie N Heap; Margaret Brewinski-Isaacs Journal: AIDS Date: 2013-11 Impact factor: 4.177